The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.
Frustrated with congressional Republican inaction on major pieces of his agenda, President Trump cut deals with Democrats on a short-term increase in the debt ceiling and funding the government. Then to the surprise and consternation of his base, Trump agreed to work on a deal to extend DACA, a Democratic priority. But what does Trump’s new interest in working with Democrats mean for healthcare policy-making? That is not yet clear.
At some point in the life of a pharmaceutical company, a whistleblower is likely to come forward with allegations of wrongdoing. The intricacies of marketing alone can create a minefield of potential mistakes. Your best defense begins now.
Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.
Want to ensure you have a strong compliance program already in place should you ever fall under the microscope of the DOJ? Here are 11 topics to evaluate first.
Ask life sciences industry leaders and experts about blockchain and you will hear it called everything from “a game changer” to “a major disrupter.” According to the hype, the technology behind cryptocurrencies, like bitcoin, is going to completely transform day-to-day operations for life sciences companies.
Newly-appointed Pfenex CEO, Eef Schimmelpennink, faces the challenge of determining how to adapt Pfenex to a constantly changing future. Though it's still very early in his tenure, Schimmelpennink highlights some areas he will keep in mind as he steers Pfenex's future biosimilars onto the market.
New York City has long aspired to become a life sciences hub, but while the city seems to have all the elements necessary to foster such industry growth, it has continually fallen short of this goal. New York currently ranks a distant third behind both Greater Boston and the San Francisco Bay Area, and there’s some work to do if it hopes to catch up.
Generic drug prices are falling. For confirmation, look no further than the recent earnings reports from generic manufacturers and pharmaceutical wholesalers whose profits from distributing generic pharmaceuticals are also declining.
These tales prove that it's possible to snatch victory from the hands of regulatory defeat when responding to adversity with open-minded persistence.
Serialization in the pharmaceutical sector is a direct response to the problems of counterfeit, stolen, and gray-market drugs. There's been a huge incentive for counterfeiters to duplicate high-profit-margin products. According to the 2016 Brand Protection and Product Traceability Market Research Report from PMMI, the black market for counterfeit drugs is about $75 billion annually.
In this final installment of a three-part series, managing directors Jonathan Kfoury and Ricardo Brau of L.E.K. Consulting share their perspectives on six biosimilar company archetypes, emerging biosimilar development and business strategies (as well as mistakes to avoid), and the market’s future.
On May 11, Scott Gottlieb, M.D., officially became the 23rd commissioner of the U.S. Food and Drug Administration (FDA). Dr. Gottlieb has previous FDA experience, having served as deputy commissioner for medical and scientific affairs, among other positions, during the George W. Bush administration.
While attending BIO’s 2017 annual meeting in San Diego this past June, I had the opportunity to conduct an in-person interview with David Hung, the CEO of Axovant Sciences. In 2016, the former founder of Medivation navigated the successful acquisition of his company by Pfizer for $14.3 billion. Though many might credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, I would argue that there are a number of other predictors that should be evaluated when anticipating future success.
Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.
In the September issue of Life Science Leader, we will feature an article on how Allergan’s Chairman, President, and CEO, Brent Saunders, conceived and created Allergan’s now-famous social contract. You’ll likely be stunned at the approach that was taken.
According to Sanat Chattopadhyay, president of the Merck Manufacturing Division (MMD) and subject of Life Science Leader’s August 2017 feature article, female leaders are going to shape the world in the future.
While it is a little early in the Merck Manufacturing Division (MMD) transformation to determine what, if anything, he would have done differently, it is likely Sanat Chattopadhyay will explore this exercise in the near future.
Though BIO launched its call for sessions on Thursday, September 14, 2017, the kickoff of the annual meeting’s formal educational planning process did not officially begin until Monday, September 18, 2017, at least for the planning committee that is. For while Sarah Arth, VP of education, and her team probably began planning shortly after the conclusion of this year’s meeting in San Diego, it was on this day that I, along with my fellow co-chairs Nessan Bermingham, CEO, president, and founder of Intellia Therapeutics; Leslie Williams, CEO of ImmusanT; and 57 other members of the 2018 program planning committee formally met to discuss plans for the educational component of the 2018 convention in Boston. As a committee, we realize that the show in San Diego will be tough to top. After all, it had 16,123 attendees hailing from 74 countries and 48 states. Further, the show boasts having had more than 1,800 exhibitors and facilitated more than 41,400 partnering meetings between 3,500 participating organizations. Finally, last year’s conference had more than 145 educational sessions, covering 18 tracks and involved more than 800 speakers! However, we are up for the challenge. Our goal is to have can’t-miss content, meaning — someone would rather miss a one-on-one partnering meeting than miss one of the educational sessions. But to do this we, of course, need people willing to submit interesting and novel session proposals — and not just a rehash of one that seemed to work well last year.
Next week, BIO will invite biopharmaceutical industry experts to submit educational topic session proposals for the 2018 BIO International Convention in Boston, June 4 - 7. The 2018 call for sessions and speakers opens on Thursday, September 14, and closes on Thursday, October 12, 2017. As I have (once again) agreed to serve as a BIO educational program planning committee co-chair, I have a vested interest in its success. My goal in helping biopharma’s largest and most influential global event, is to assist in creating such a strong educational program, that when you see this year’s offerings you will deem BIO 2018 in Boston as a must attend. However, I need your help to pull this off. The only question is: Will your participation be active — or passive?
